Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion

Authors: Pamela A Havre, Long H Dang, Kei Ohnuma, Satoshi Iwata, Chikao Morimoto, Nam H Dang

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

CD26/dipeptidyl peptidase IV (DPPIV) is a multifunctional membrane protein with a key role in T-cell biology and also serves as a marker of aggressive cancers, including T-cell malignancies.

Methods

Versican expression was measured by real-time RT-PCR and Western blots. Gene silencing of versican in parental Karpas 299 cells was performed using transduction-ready viral particles. The effect of versican depletion on surface expression of MT1-MMP was monitored by flow cytometry and surface biotinylation. CD44 secretion/cleavage and ERK (1/2) activation was followed by Western blotting. Collagenase I activity was measured by a live cell assay and in vesicles using a liquid-phase assay. Adhesion to collagen I was quantified by an MTS assay.

Results

Versican expression was down-regulated in CD26-depleted Karpas 299 cells compared to the parental T-ALCL Karpas 299 cells. Knock down of versican in the parental Karpas 299 cells led to decreased MT1-MMP surface expression as well as decreased CD44 expression and secretion of the cleaved form of CD44. Parental Karpas 299 cells also exhibited higher collagenase I activity and greater adhesion to collagenase I than CD26-knockdown or versican-knockdown cells. ERK activation was also highest in parental Karpas 299 cells compared to CD26-knockdown or versican-knockdown clones.

Conclusions

Our data indicate that CD26 has a key role in cell adhesion and invasion, and potentially in tumorigenesis of T-cell lines, through its association with molecules and signal transduction pathways integral to these processes.
Appendix
Available only for authorised users
Literature
1.
Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, et al: A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 2010, 6 (6): 603-615. 10.1016/j.stem.2010.04.001.CrossRefPubMed
2.
de Andrade CF, Bigni R, Pombo-de-Oliveira MS, Alves G, Pereira DA: CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. J Enzyme Inhib Med Chem. 2009, 24 (3): 708-714. 10.1080/14756360802334800.CrossRefPubMed
3.
De Chiara L, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Cordero OJ, Martinez-Ares D, Paez de la Cadena M: Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer. 2010, 10: 333-10.1186/1471-2407-10-333.CrossRefPubMedPubMedCentral
4.
Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E, Kokubun S: Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology. 2009, 55 (4): 432-440. 10.1111/j.1365-2559.2009.03399.x.CrossRefPubMedPubMedCentral
5.
Varona A, Blanco L, Perez I, Gil J, Irazusta J, Lopez JI, Candenas ML, Pinto FM, Larrinaga G: Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer. 2010, 10: 193-10.1186/1471-2407-10-193.CrossRefPubMedPubMedCentral
6.
Wesley UV, McGroarty M, Homoyouni A: Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 2005, 65 (4): 1325-1334. 10.1158/0008-5472.CAN-04-1852.CrossRefPubMed
7.
Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S: Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. 2002, 62 (10): 2753-2757.PubMed
8.
Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS, Morimoto C, Dang NH: CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 2005, 65 (15): 6950-6956. 10.1158/0008-5472.CAN-05-0647.CrossRefPubMed
9.
Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Yoshikawa N, Shimizu N, Iwata S, Tanaka H, Dang NH, Morimoto C: CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA. 2004, 101 (39): 14186-14191. 10.1073/pnas.0405266101.CrossRefPubMedPubMedCentral
10.
Fox DA, Hussey RE, Fitzgerald KA, Acuto O, Poole C, Palley L, Daley JF, Schlossman SF, Reinherz EL: Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol. 1984, 133 (3): 1250-1256.PubMed
11.
Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C: Comitogenic effect of solid-phase immobilized anti-1 F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol. 1990, 144 (11): 4092-4100.PubMed
12.
Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF, Morimoto C: Cell surface modulation of CD26 by anti-1 F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol. 1990, 145 (12): 3963-3971.PubMed
13.
Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C: Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 1991, 147 (8): 2514-2517.PubMed
14.
Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, Improta S, Sorio R, Monfardini S, Pinto A: The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin’s lymphomas/leukemias. Blood. 1995, 86 (12): 4617-4626.PubMed
15.
Dang NH, Aytac U, Sato K, O’Brien S, Melenhorst J, Morimoto C, Barrett AJ, Molldrem JJ: T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol. 2003, 121 (6): 857-865. 10.1046/j.1365-2141.2003.04365.x.CrossRefPubMed
16.
Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, Ono M, Shoji A, Sakuma T, Kuwabara H, et al: Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol. 2008, 26 (25): 4100-4108. 10.1200/JCO.2007.14.2331.CrossRefPubMed
17.
Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, et al: Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res. 2007, 13 (14): 4191-4200. 10.1158/1078-0432.CCR-07-0110.CrossRefPubMed
18.
Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y, Iris L: Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol. 1990, 137 (4): 895-905.PubMedPubMedCentral
19.
Le Naour F, Andre M, Greco C, Billard M, Sordat B, Emile J-F, Lanza F, Boucheix C, Rubinstein E: Profiling of the Tetraspanin web of human colon cancer cells. Mol Cell Proteomics. 2006, 5 (5): 845-857. 10.1074/mcp.M500330-MCP200.CrossRefPubMed
20.
Stange T, Kettmann U, Holzhausen HJ: Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. Eur J Histochem. 2000, 44 (2): 157-164.PubMed
21.
Javidroozi M, Zucker S, Chen WT: Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis Markers. 2012, 32 (5): 309-320. 10.1155/2012/706745.CrossRefPubMedPubMedCentral
22.
Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH: CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer. 2009, 101 (6): 983-991. 10.1038/sj.bjc.6605236.CrossRefPubMedPubMedCentral
23.
Wight TN: Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002, 14 (5): 617-623. 10.1016/S0955-0674(02)00375-7.CrossRefPubMed
24.
Yamagata M, Yamada KM, Yoneda M, Suzuki S, Kimata K: Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem. 1986, 261 (29): 13526-13535.PubMed
25.
26.
Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB: The interaction of versican with its binding partners. Cell Res. 2005, 15 (7): 483-494. 10.1038/sj.cr.7290318.CrossRefPubMed
27.
Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ: The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009, 28 (1–2): 233-245.CrossRefPubMed
28.
Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK: Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010, 277 (19): 3904-3923. 10.1111/j.1742-4658.2010.07800.x.CrossRefPubMed
29.
Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, Spessotto P, Perissinotto D, Morgelin M, Mucignat MT, Colombatti A, Perris R: Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem. 2002, 277 (49): 47626-47635. 10.1074/jbc.M206521200.CrossRefPubMed
30.
Dolo V, Adobati E, Canevari S, Picone MA, Vittorelli ML: Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis. 1995, 13 (4): 277-286. 10.1007/BF00133483.CrossRefPubMed
31.
Wolf K, Muller R, Borgmann S, Brocker EB, Friedl P: Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood. 2003, 102 (9): 3262-3269. 10.1182/blood-2002-12-3791.CrossRefPubMed
32.
Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, et al: Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol. 2004, 167 (4): 769-781. 10.1083/jcb.200408028.CrossRefPubMedPubMedCentral
33.
Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, Sato H: Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res. 2004, 64 (3): 1044-1049. 10.1158/0008-5472.CAN-03-1843.CrossRefPubMed
34.
Gingras D, Beliveau R: Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. Biochim Biophys Acta. 2010, 1803 (1): 142-150. 10.1016/j.bbamcr.2009.04.011.CrossRefPubMed
35.
Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, Sato H, Tojo H, Yana I, Seiki M: CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 2002, 21 (15): 3949-3959. 10.1093/emboj/cdf411.CrossRefPubMedPubMedCentral
36.
Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M: Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001, 153 (5): 893-904. 10.1083/jcb.153.5.893.CrossRefPubMedPubMedCentral
37.
Ladeda V, Aguirre Ghiso JA, Bal de Kier Joffe E: Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells. Exp Cell Res. 1998, 242 (2): 515-527. 10.1006/excr.1998.4094.CrossRefPubMed
38.
Williams KC, Coppolino MG: Phosphorylation of membrane type 1-matrix metalloproteinase (MT1-MMP) and its vesicle-associated membrane protein 7 (VAMP7)-dependent trafficking facilitate cell invasion and migration. J Biol Chem. 2011, 286 (50): 43405-43416. 10.1074/jbc.M111.297069.CrossRefPubMedPubMedCentral
39.
Zucker S, Hymowitz M, Conner CE, DiYanni EA, Cao J: Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest. 2002, 82 (12): 1673-1684. 10.1097/01.LAB.0000041713.74852.2A.CrossRefPubMed
40.
Kean MJ, Williams KC, Skalski M, Myers D, Burtnik A, Foster D, Coppolino MG: VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci. 2009, 122 (Pt 22): 4089-4098.CrossRefPubMed
41.
Evans RD, Itoh Y: Analyses of MT1-MMP activity in cells. Methods Mol Med. 2007, 135: 239-249. 10.1007/978-1-59745-401-8_15.CrossRefPubMed
42.
Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R: ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012, 72 (1): 365-374. 10.1158/0008-5472.CAN-11-1831.CrossRefPubMed
43.
Tanimura S, Asato K, Fujishiro SH, Kohno M: Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun. 2003, 304 (4): 801-806. 10.1016/S0006-291X(03)00670-3.CrossRefPubMed
44.
Gingras D, Bousquet-Gagnon N, Langlois S, Lachambre MP, Annabi B, Beliveau R: Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett. 2001, 507 (2): 231-236. 10.1016/S0014-5793(01)02985-4.CrossRefPubMed
45.
Taraboletti G, D’Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V: Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol. 2002, 160 (2): 673-680. 10.1016/S0002-9440(10)64887-0.CrossRefPubMedPubMedCentral
46.
Hakulinen J, Sankkila L, Sugiyama N, Lehti K, Keski-Oja J: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J Cell Biochem. 2008, 105 (5): 1211-1218. 10.1002/jcb.21923.CrossRefPubMed
47.
Chun TH, Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, Birkedal-Hansen H, Allen ED, Weiss SJ: MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol. 2004, 167 (4): 757-767. 10.1083/jcb.200405001.CrossRefPubMedPubMedCentral
48.
Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A: MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 2002, 16 (6): 555-564. 10.1096/fj.01-0790com.CrossRefPubMed
49.
Gialeli C, Theocharis AD, Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278 (1): 16-27. 10.1111/j.1742-4658.2010.07919.x.CrossRefPubMed
50.
Dang NH, Torimoto Y, Schlossman SF, Morimoto C: Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1 F7 and VLA integrin family. J Exp Med. 1990, 172 (2): 649-652. 10.1084/jem.172.2.649.CrossRefPubMed
51.
Loster K, Zeilinger K, Schuppan D, Reutter W: The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun. 1995, 217 (1): 341-348. 10.1006/bbrc.1995.2782.CrossRefPubMed
52.
Cheng HC, Abdel-Ghany M, Pauli BU: A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem. 2003, 278 (27): 24600-24607. 10.1074/jbc.M303424200.CrossRefPubMed
53.
Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC: Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006, 66 (6): 3034-3043. 10.1158/0008-5472.CAN-05-2177.CrossRefPubMed
54.
55.
Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT: Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA. 1997, 94 (15): 7959-7964. 10.1073/pnas.94.15.7959.CrossRefPubMedPubMedCentral
56.
Wang Y, McNiven MA: Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol. 2012, 196 (3): 375-385. 10.1083/jcb.201105153.CrossRefPubMedPubMedCentral
57.
Tague SE, Muralidharan V, D’Souza-Schorey C: ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci USA. 2004, 101 (26): 9671-9676. 10.1073/pnas.0403531101.CrossRefPubMedPubMedCentral
58.
Takino T, Tsuge H, Ozawa T, Sato H: MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem Biophys Res Commun. 2010, 396 (4): 1042-1047. 10.1016/j.bbrc.2010.05.059.CrossRefPubMed
59.
Howe AK, Aplin AE, Juliano RL: Anchorage-dependent ERK signaling–mechanisms and consequences. Curr Opin Genet Dev. 2002, 12 (1): 30-35. 10.1016/S0959-437X(01)00260-X.CrossRefPubMed
60.
Gonzalo P, Moreno V, Galvez BG, Arroyo AG: MT1-MMP and integrins: hand-to-hand in cell communication. Biofactors. 2010, 36 (4): 248-254. 10.1002/biof.99.CrossRefPubMed
61.
Ramsay AG, Marshall JF, Hart IR: Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007, 26 (3–4): 567-578.CrossRefPubMed
62.
Rahmani M, Read JT, Carthy JM, McDonald PC, Wong BW, Esfandiarei M, Si X, Luo Z, Luo H, Rennie PS, et al: Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem. 2005, 280 (13): 13019-13028.CrossRefPubMed
63.
Ghersi G, Zhao Q, Salamone M, Yeh Y, Zucker S, Chen WT: The protease complex consisting of dipeptidyl peptidase IV and Seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res. 2006, 66 (9): 4652-4661. 10.1158/0008-5472.CAN-05-1245.CrossRefPubMedPubMedCentral
64.
Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ: Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA. 1994, 91 (12): 5657-5661. 10.1073/pnas.91.12.5657.CrossRefPubMedPubMedCentral
65.
Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT: Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 2002, 277 (32): 29231-29241. 10.1074/jbc.M202770200.CrossRefPubMed
66.
Sedo A, Stremenova J, Busek P, Duke-Cohan JS: Dipeptidyl peptidase-IV and related molecules: markers of malignancy?. Exp Opin Med Diagn. 2008, 2 (6): 677-689. 10.1517/17530059.2.6.677.CrossRef
67.
Suenaga N, Mori H, Itoh Y, Seiki M: CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene. 2005, 24 (5): 859-868. 10.1038/sj.onc.1208258.CrossRefPubMed
Metadata
Title
CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion
Authors
Pamela A Havre
Long H Dang
Kei Ohnuma
Satoshi Iwata
Chikao Morimoto
Nam H Dang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-517

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis

Research article

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

Research article

The role of inflammation in HPV infection of the Oesophagus

Research article

Selenized milk casein in the diet of BALB/c nude mice reduces growth of intramammary MCF-7 tumors

Research article

ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma

Research article

The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits